OncLive TV

Paul E. Oberstein, MD, discusses the current treatment landscape of colorectal cancer.

Moshe Ornstein, MD, MA, discusses the benefit of neoadjuvant therapy in renal cell carcinoma.

Roberto Iacovelli, MD, PhD, discusses the patient eligibility criteria of the phase 2 ARIES trial in urothelial cancer.

Helen Heng-Shan Moon, MD, discusses the FDA approval of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Rohan Jeyarajah, MD, discusses aggressive treatment while preserving quality of life in patients with colorectal cancer.

Kristin G. Anderson, PhD, discusses overcoming suppressive signaling by engineering T-cells in ovarian cancer.

Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.

Andrea Facciabene, PhD, discusses investigating the use of bridging radiation therapy prior to CAR T-cell therapy in mice models.

Gunsagar Gulati, MD, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer.

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

Olivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

Alba Gonzalez-Junca, PhD, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.

Melissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.

Alessandra Larocca, MD, PhD, discusses recent advancements in relapsed/refractory multiple myeloma.

Alessandra Larocca, MD, PhD, discusses the diagnosis and management of difficult-to-treat patients with multiple myeloma.

Sarah Sammons, MD, discusses findings from the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.

David Spigel, MD, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer.

Roy S. Herbst, MD, PhD, discusses the evolving treatment landscape of targeted therapies in non–small cell lung cancer.

Charu Aggarwal, MD, MPH, discusses the optimal use of next-generation sequencing in molecular testing in non­–small cell lung cancer.

Jacqueline S. Garcia, MD, discusses the results of the phase 2 REFINE trial in patients with myelofibrosis.

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.

Michelle Miran Kim, MD, discusses optimizing individualized treatment in cancer care.

Scott K. Kindsfather, MD, discusses the evolution of reflex testing in lung cancer.

Ajay Choudhri, MD, discusses the impact of developments in artificial intelligence in cancer care.

Mridula George, MD, discusses efforts to address unmet needs in HER2-low breast cancer.

Martin Dietrich, MD, PhD, discusses the current treatment landscape of mantle cell lymphoma.